VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / First Mining Gold Corp. ("First Mining" or the "Company") (TSX:FF)(OTCQX:FFMGF)(FRANKFURT:FMG) is pleased to provide an update on the advancements being made at the Company's Springpole Gold Project ("Springpole" or the "Project") located in northwestern Ontario. First Mining is currently focused on advancing a Pre-Feasibility Study ("PFS") on the Project as well as progressing the permitting process.

Pre-Feasibility Update

As noted in First Mining's news release from January 15, 2020, a PFS on the Project is underway. This includes metallurgical and geotechnical drilling, as well as further hydrogeological studies. The Project is generally accessible by air only, except during the winter months where access is also possible via a winter ice road. The company contracted a winter ice road earlier this year to support the PFS winter drilling and metallurgical programs. This has allowed for re-supply of the camp, including diesel for drilling, at a significantly reduced cost when compared to flying necessities into camp. First Mining anticipates that the road will be accessible until early April, before the warmer temperatures and spring ice-break commences.

A detailed, two-phase, metallurgical program has been scoped and is underway. The ‘Phase 1' testwork program utilized material from the 2016 metallurgical drill program, with testing underway at the SGS laboratory in Lakefield, Ontario. A second ‘Phase 2' test work program is being completed using additional core material obtained from three new metallurgical holes drilled in early 2020. The main objective of the program is to optimize flotation and cyanide leaching conditions and provide design criteria for the PFS.

Drills were mobilized to the Project in early February. In addition to the three metallurgical drill holes completed, additional holes have been strategically located to support both hydrogeology and geotechnical assessment. This combined geotechnical-hydrogeological drill program, which has already commenced and is anticipated to be completed later this year, will consist of 10 holes in the proposed pit wall and coffer dam areas. The results of this drilling will help guide how the ground water moves within the region and provide a better sense of the pit slope stability, which in turn may help improve strip ratio estimates. A further 14 geotechnical drill holes, in addition to a number of test pits, are also planned as part of the PFS on-site work to test the proposed plant site, tailings and waste storage areas.

Trade-off studies have also been initiated as part of the PFS work program. These studies focus on the tailings storage facility, mine plan optimization, process recovery validation and optimization, power supply and other required infrastructure. These desktop studies aim to uncover potential areas for value optimization and improvement.

Ken Engquist, COO of First Mining, stated "We are excited with the progress we are making in advancing the PFS work program at Springpole. We believe there are many areas for improvement on the existing 2019 PEA economics as we de-risk the Project technically. Springpole is a unique project given its size and scale, and an asset with a meaningful production profile once built. We are excited to unlock this potential by moving the Project closer to a construction decision."

In response to the ongoing concerns surrounding COVID-19 and in order to ensure the health and safety of all its employees at Springpole, First Mining announced on March 24, 2020 the early demobilization of contractors on-site at Springpole and a reduction in staffing to care and maintenance levels. Apart from the field data collection, most of the remaining PFS work will be completed remotely, and as such First Mining does not anticipate any significant delays in completing the PFS. However, given the need to complete additional on-site work in support of the PFS at a later date, and the evolving global environment in respect of COVID-19, First Mining anticipates that the PFS results will now be released in early 2021.

Permitting Update

Consultations are ongoing with the Indigenous communities in support of the advancement of permitting of the Project. In the provincial Environmental Assessment ("EA") process, there are two main stages: development of the Terms of Reference ("ToR") and development of the EA report.

The ToR is a work plan which will outline how the EA will be prepared, with the ToR document detailing the community consultation and engagement plans (for the Indigenous communities, government and other stakeholders), baseline studies, key components of the project and a range of alternatives that will be considered. First Mining submitted a revised draft ToR for review to the Ministry of Environment, Conservation and Parks ("MECP") on February 20, 2020, with MECP requesting a 45-day review period. Simultaneously, First Mining also submitted a revised draft to the Indigenous communities, provincial and federal government agencies, and various municipal governments near the Project. First Mining is working towards submission of the final ToR in April 2020, with receipt of the final approved ToR expected by the end of Q2 2020.

First Mining has also been collecting baseline data and undertaking consultation meetings to advance the federal and provincial EA processes. In 2019, First Mining completed a data gap assessment on the environmental baseline work to identify any remaining work requirements for the Project. Data collection programs as part of this assessment to further advance the EA process included terrestrial studies (species at risk, a fish and fish habitat study), surface water quality monitoring, geotechnical studies, traditional and ecological knowledge studies, hydrogeology, groundwater well pumping tests, and tailings and mine rock geochemical characterization.

First Mining elected to continue to stay in the Canadian Environmental Assessment Act, 2012 permitting process and not the newly enacted Impact Assessment Act process ("IAA"). First Mining is working on the Environmental Impact Statement ("EIS") as per EIS Guidelines that were issued to the Company on June 19, 2018.

The balance of the environmental program for the year involves continued baseline studies (described above), with a goal of collecting all of the data required under the ToR for compilation of an EIS by the end of the year, and submission of the EIS in 2021. While First Mining does not currently foresee any significant delays to this process, the Company acknowledges the potential for consultation timeframes to be impacted by the important prioritization of the health and safety of the Indigenous communities that First Mining is in consultation with.

Despite these uncertainties, First Mining is well financed to continue moving the Springpole project forward in 2020, having closed an $8.5 million equity financing on March 6, 2020.

Filing of Company's Year-End Filings

First Mining has filed on SEDAR its audited financial statements, management's discussion and analysis and annual information form for the financial year ended December 31, 2019.

In addition, concurrently with the annual Canadian filings set out above, the Company has filed its annual report on Form 40-F with the U.S. Securities and Exchange Commission ("SEC"). The Form 40-F incorporates by reference the above annual Canadian filings of First Mining, and is available on the SEC's website, EDGAR, at www.sec.gov/edgar.shtml.

All the above noted filings are also available on First Mining's website at www.firstmininggold.com, and printed copies of the filings are available free of charge to First Mining shareholders upon written request.

Qualified Person

Hazel Mullin, P.Geo., Director, Data Management and Technical Services of First Mining, is a "Qualified Person" for the purposes of NI 43-101, and she has reviewed and approved the scientific and technical disclosure contained in this news release.

About First Mining Gold Corp.

First Mining Gold Corp. is a Canadian-focused gold exploration and development company advancing a large resource base of 7.4 million ounces of gold in the Measured and Indicated categories and 3.8 million ounces of gold in the Inferred category. First Mining's primary focus is the development and permitting of its Springpole Gold Project and the advanced exploration of its Goldlund Gold Project, both located in northwestern Ontario. Springpole is one of the largest undeveloped gold assets in Canada, with permitting and a Pre-Feasibility Study underway. Goldlund is an advanced exploration stage asset where drilling in 2020 is planned to define both the extension of the existing resource area and to better define the regional scale potential. First Mining's eastern Canadian property portfolio also includes Cameron, Pickle Crow, Hope Brook, Duparquet, Duquesne, and Pitt.

First Mining was created in 2015 by Mr. Keith Neumeyer, founding President and CEO of First Majestic Silver Corp.

ON BEHALF OF FIRST MINING GOLD CORP.

Daniel W. Wilton
Chief Executive Officer and Director

For further information, please contact:

Mal Karwowska | Vice President, Corporate Development & Investor Relations
Direct: 604.639.8824 | Toll Free: 1.844.306.8827 | Email: info@firstmininggold.com
www.firstmininggold.com

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date of this news release. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "plans", "projects", "intends", "estimates", "envisages", "potential", "possible", "strategy", "goals", "objectives", or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions.

Forward-looking statements in this news release relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, but are not limited to, statements with respect to: (i) the PFS for Springpole being completed by early 2021; (ii) the winter ice road at the Project being accessible until the end of March; (iii) the Company's plans to complete a 10-hole geotechnical-hydrogeological drill program at the Project by summer 2020 (iv) the Company's expectations that the results of the geotechnical-hydrogeological drill program at the Project will help guide how the ground water moves within the region and provide a better sense of the pit slope stability; (v) the Company's plans to drill a further 14 geotechnical drill holes at the Project, in addition to a number of test pits, to test the proposed plant site, tailings and waste storage areas; (vi) the timing and expected results of trade-off studies at the Project as part of the PFS; (vii) the Company's belief that there are many areas for improvement on the existing economics of the Project; (viii) most of the remaining PFS-related work being completed remotely: (ix) the timing for completing and submitting the final ToR; (x) receipt of approval of the final ToR in Q2 2020; (xi) the Company's primary focus on developing and permitting Springpole and the advanced exploration of its Goldlund Gold Project; and (xii) realizing the value of the Company's gold projects for the Company's shareholders. All forward-looking statements are based on First Mining's or its consultants' current beliefs as well as various assumptions made by them and information currently available to them. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation the Company's business, operations and financial condition potentially being materially adversely affected by the outbreak of epidemics, pandemics or other health crises, such as COVID-19, and by reactions by government and private actors to such outbreaks; risks to employee health and safety as a result of the outbreak of epidemics, pandemics or other health crises, such as COVID-19, that may result in a slowdown or temporary suspension of operations at some or all of the Company's mineral properties as well as its head office; fluctuations in the spot and forward price of gold, silver, base metals or certain other commodities; fluctuations in the currency markets (such as the Canadian dollar versus the U.S. dollar); changes in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins and flooding); the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities, indigenous populations and other stakeholders; availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development; title to properties.; and the additional risks described in the Company's Annual Information Form for the year ended December 31, 2019 filed with the Canadian securities regulatory authorities under the Company's SEDAR profile at www.sedar.com, and in the Company's Annual Report on Form 40-F filed with the SEC on EDGAR.

First Mining cautions that the foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements to make decisions with respect to First Mining, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. First Mining does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by the Company or on our behalf, except as required by law.

Cautionary Note to United States Investors

This news release has been prepared in accordance with the requirements of the securities laws in effect in Canada, which differ from the requirements of U.S. securities laws. Unless otherwise indicated, all resource and reserve estimates included in this news release have been prepared in accordance with NI 43-101 and the Canadian Institute of Mining, Metallurgy, and Petroleum 2014 Definition Standards on Mineral Resources and Mineral Reserves. NI 43-101 is a rule developed by the Canadian Securities Administrators which establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. Canadian standards, including NI 43-101, differ significantly from the requirements of the SEC, and mineral resource and reserve information contained herein may not be comparable to similar information disclosed by U.S. companies. In particular, and without limiting the generality of the foregoing, the term "resource" does not equate to the term "reserves". Under U.S. standards, mineralization may not be classified as a "reserve" unless the determination has been made that the mineralization could be economically and legally produced or extracted at the time the reserve determination is made. The SEC's disclosure standards normally do not permit the inclusion of information concerning "measured mineral resources", "indicated mineral resources" or "inferred mineral resources" or other descriptions of the amount of mineralization in mineral deposits that do not constitute "reserves" by U.S. standards in documents filed with the SEC. Investors are cautioned not to assume that any part or all of mineral deposits in these categories will ever be converted into reserves. U.S. investors should also understand that "inferred mineral resources" have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an "inferred mineral resource" will ever be upgraded to a higher category. Under Canadian rules, estimated "inferred mineral resources" may not form the basis of feasibility or pre-feasibility studies except in rare cases. Investors are cautioned not to assume that all or any part of an "inferred mineral resource" exists or is economically or legally mineable. Disclosure of "contained ounces" in a resource is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute "reserves" by SEC standards as in-place tonnage and grade without reference to unit measures. The requirements of NI 43-101 for identification of "reserves" are also not the same as those of the SEC, and reserves reported by the Company in compliance with NI 43-101 may not qualify as "reserves" under SEC standards. Accordingly, information concerning mineral deposits set forth herein may not be comparable with information made public by companies that report in accordance with U.S. standards.

SOURCE: First Mining Gold Corp.

ReleaseID: 583201

VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) has provided audited financial results for the fourth quarter and year of 2019 for its British Columbia-based joint venture, Pure Sunfarms (PSF).

Financial Data

All comparable figures are for the year and quarter ended December 31, 2018.

Net sales, consisting entirely of dried cannabis, for the year and fourth quarter of 2019 were $82.8 million and $12.1 million, respectively, compared to $4.9 million and $4.7 million.
"All-in" cost of cultivation (including depreciation) for the year was $0.78 per gram and for the fourth quarter was $0.66 per gram.
Gross margin (before non-cash adjustments to the fair value of inventory and biological assets and inventory impairment) for the year and fourth quarter was 76% and 83% compared to 69% and 71%.
Selling, general and administrative expenses for the year and fourth quarter were $10.4 million and $3.0 million compared to $3.4 million and $1.3 million.
EBITDA for 2019 was $54.1 million, resulting in an EBITDA margin of 65%, compared to $0.0 million in 2018.
EBITDA in the fourth quarter of 2019 was $6.9 million, an EBITDA margin of 57%, compared to $2.1 million in the fourth quarter of 2018, an EBITDA margin of 44%.

Sales and Operating Highlights

Pure Sunfarms sold approximately 26,000 kilograms of flower and trim in 2019 at an average price of approximately $2.90 per gram. Roughly 92% of 2019 sales were to the bulk wholesale channel and 8% to the branded retail channel. Fourth quarter sales were over 1,100 kilograms averaging over C$3.59 per gram. During the fourth quarter, all cannabis sales were branded retail sales to provincial distribution boards and for the most part represented replenishment orders during the quarter.
PSF recognized revenue of $8.1 million upon the completion of the Settlement Agreement with Emerald in Q4.
Two of the three significant initial retail shipments to provincial boards occurred before and after the fourth quarter.
PSF expanded its distribution to Alberta in Q1 2020, thereby increasing its market presence to three of Canada's four most populous provinces (also including Ontario and British Columbia) or nearly two-thirds of the Canadian recreational cannabis market (by population).
PSF remained the top-selling brand of dried flower with the Ontario Cannabis Store by both dollars sold and kilograms sold year to date ended February 29, 2020, achieving a 13.5% market share (by kilograms sold), with two of the top four dried cannabis products by both dollars sold and kilograms sold, and the top-selling dried cannabis product by both dollars sold and kilograms sold.
It continues to work toward distribution opportunities in other provinces.
PSF just recently launched a new large-format 28-gram (1 ounce) package.
It received approval from Health Canada to operate the final components of its 65,000 square foot, state-of-the-art processing center located within the 1.1 million square foot Delta 3 greenhouse facility. The expanded processing area will enable PSF to generate additional production cost efficiencies, further elevate the quality of its products, expand its product offerings and increase its processing throughput. The processing centre includes an extraction area that will have processing capacity of 35,000 kilograms of biomass annually. The new area has been designed to satisfy European Union GMP compliance and certification, which Pure Sunfarms is currently pursuing.
PSF continues to prepare for the introduction of new product forms under Cannabis 2.0, expected to commence in the second half of this year.

Management Comment

"In the first full year of legal recreational cannabis sales in Canada, our Pure Sunfarms joint venture achieved stellar outcomes in operations, sales as well as financial performance," said Riaz Bandali, President and CEO, Emerald Health Therapeutics. "PSF continues to set standards for cultivation efficiency and overall operating costs in the sector and has demonstrated an ability to deliver a compelling product and value proposition to consumers and other Licensed Producers."

"We are proud of PSF's success and pleased that we continue to be a significant partner in this tremendous company. We are also very pleased with the licensing and scale-up into production of our two wholly-owned cultivation facilities in Richmond, BC, and St. Eustache, Quebec, which now serve as our source of cannabis supply for our product development efforts as well as for our medical and recreational customers. These two facilities, along with our position in PSF, provide Emerald with three distinct operating assets producing differentiated and complementary products to serve the market."

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is committed to cutting edge cannabis science to create new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products. With an emphasis on innovation and production excellence, Emerald's three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities. These assets, all in full production, include: its Richmond, BC-based organic-certified greenhouse operation (78,000 square feet); Verdélite, its premium craft cannabis production indoor facility in St. Eustache, Québec (88,000 square foot); and Pure Sunfarms, its 42.6%-owned joint venture in Delta, BC, producing high quality, affordably priced products (1.1 million square feet). Its Emerald Naturals joint venture has launched a new natural wellness product category with its non-cannabis endocannabinoid-supporting product line and is expanding distribution across Canada.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5
Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Non-GAAP Financial Measures

This press release contains references to EBITDA which is not a measure that has any standardized meaning prescribed by IFRS and is therefore referred to as a "non-GAAP measure". Non-GAAP measures used by the Company may not be comparable to similar measures used by other companies. EBITDA is defined as "income (loss) before interest expenses, taxes, depreciation, amortization, foreign exchange losses, and the net impact of biological asset values on income."

The Company uses this non-GAAP measure because it provides additional information regarding performance of Pure Sunfarms' overall business that is not otherwise reflected under IFRS.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include expansion and launch of Pure Sunfarms product lines; Pure Sunfarms securing distribution in additional provinces; Pure Sunfarms production of oils; obtaining required regulatory approvals; production and processing capacity of various facilities; expansion or conversion of facilities and the timing thereof; obtaining additional cultivation licenses and other permits; payments of amounts owed to and owed by Emerald; resolution of disputes; broadening distribution of non-cannabis endocannabinoid products; and anticipated production costs.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, results of operations; changes in business focus and strategy; agreements with third parties; changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; as well as the risk factors described in the Company's annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

SOURCE: Emerald Health Therapeutics, Inc.

ReleaseID: 583277

WALTHAM, MA / ACCESSWIRE / March 31, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive topline data in its study using the Ocular Bandage Gel ("OBG") eye drops in patients with dry eye. OBG is a proprietary crosslinked version of the natural polymer hyaluronic acid ("HA") that is designed to stay longer on the corneal surface. OBG has recently demonstrated statistical significance in a pivotal study for the acceleration of wound healing in patients that have undergone photorefractive keratectomy surgery. OBG has now demonstrated that it also helps in the treatment of patients with dry eye.

This uniquely designed study confirmed the ability of EyeGate's OBG eye drops to demonstrate improvement of the ocular surface for several important ophthalmic endpoints. Significantly, OBG eye drops showed an improvement in central corneal region staining, high order ocular aberrations ("HOA") and best corrected visual acuity ("BCVA"), outperforming the positive control, Allergan's Refresh Preservative-Free lubricant. This is consistent with the data from EyeGate's first pilot study where OBG showed positive results in the staining of the central corneal region against a vehicle control.

This investigator masked study enrolled 20 patients, or 40 eyes, at three sites in the United States. The unique study design used the patient as their own control in order to reduce interpatient variability. Accordingly, both eyes of the patient had to qualify where one eye was randomized to receive OBG eye drops and the other eye was randomized to receive Allergan's Refresh lubricant eye drops.

The positive results demonstrating corneal surface improvement include:

Central Corneal Staining

OBG demonstrated a 25% improvement from baseline versus 15% for Allergan's Refresh lubricant. In addition, the study demonstrated that OBG works quickly relative to Allergan's Refresh lubricant, showing a 10% improvement at Day 7 compared to no improvement in the control group.

HOA and BCVA

OBG demonstrated an 8.2% improvement in HOA over the two-week period, whereas Allergan's Refresh lubricant showed short-term worsening in aberrations and no benefit over the two week period. The HOA results represent the irregularities on the corneal surface likely to impact quality of vision and best corrected visual acuity. For the BCVA endpoint, OBG demonstrated a trend of improvement over the two-week period, whereas Allergan's Refresh lubricant did not.

TFBUT

OBG demonstrated a positive trend with a modest benefit over the control, increasing tear film stability by approximately 40% from baseline over a two-week period, compared to approximately 33% using Allergan's Refresh lubricant.

Additionally, this study confirmed for the first time in the clinic that OBG does not cause blurriness. Vision was assessed at 30 and 60 minutes post application for both OBG and Allergan's Refresh lubricant and demonstrated that there was no change in vision for OBG versus a small negative change for Allergan's Refresh lubricant at the 30 minute time point.

"I am excited with the results, demonstrating that EyeGate's crosslinked HA OBG eye drops improved the ocular surface of dry eye patients in a very uniquely designed study," said Victor Perez M.D., Scientific Director of the Ocular Immunology Center in Ophthalmology at Duke University School of Medicine. "Also, the correlation between the staining of the central corneal region, high order ocular aberrations and best corrected visual acuity clearly demonstrates improved health of the ocular surface."

"We are very pleased with the results of this study," said Stephen From, EyeGate's CEO. "The fact that we were able to repeat the improvement in staining of the central corneal region in this second study going against Allergan's Refresh lubricant is very exciting. We plan to meet with the FDA in the near future to confirm that this endpoint is suitable to move forward into the pivotal study with the OBG eye drop."

About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye.

EyeGate's lead product, Ocular Bandage Gel ("OBG"), is based on a modified form of the natural polymer hyaluronic acid. The product is applied as a clear topical gel, to the damaged ocular surface and possesses unique properties that help hydrate, protect, and heal the ocular surface. EyeGate is in the clinic for two different patient populations: (1) photorefractive keratectomy ("PRK") surgery to demonstrate corneal wound repair after refractive surgery; and (2) punctate epitheliopathies ("PE"), specifically in patients with dry eye.

The objective of OBG is to re-epithelialize the cornea, reduce the risk of infection, improve symptoms, and improve ocular surface integrity. Often, current treatments fall short because they are ineffective in protecting and enabling corneal re-epithelialization.

If EyeGate receives FDA approval following successful completion of the PRK pivotal study, EyeGate believes OBG will be the only prescription hyaluronic acid ("HA") eye drop in the U.S. and the only eye drop in the U.S. approved for the healing of corneal epithelial defects. Additionally, if the clinical trials for patients with PE are successful, EyeGate believes OBG will be the only HA eye drop in the U.S. approved for the treatment of Dry Eye.

For more information, please visit www.EyeGatePharma.com.

EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page (https://www.facebook.com/ EyeGatePharma/), corporate Twitter account (https://twitter.com/EyeGatePharma), and LinkedIn page (https://www.linkedin.com/company/135892/) as channels of distribution of information about EyeGate and its product candidates. Such information may be deemed material information, and EyeGate may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor EyeGate's website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts. The social media channels that EyeGate intends to use as a means of disclosing the information described above may be updated from time to time as listed on EyeGate's investor relations website.

Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate's products, including EyeGate's OBG product, its EGP-437 Combination Product, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading "Risk Factors" contained in EyeGate's Annual Report on Form 10-K filed with the SEC on March 4, 2020 or described in EyeGate's other public filings. EyeGate's results may also be affected by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Contact
Joseph Green/Laine Yonker
Edison Advisors for EyeGate Pharmaceuticals
646-653-7030/7035
jgreen@edisongroup.com/lyonker@edisongroup.com

SOURCE: EyeGate Pharmaceuticals, Inc.

ReleaseID: 583242

NORTHVALE, NJ / ACCESSWIRE / March 31, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP) a specialty pharmaceutical company developing niche generic products, announced today that marketing partner Lannett Company, Inc. ("Lannett"), has commenced product launch of Elite's generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules. Adderall XR®, including generic versions, have an estimated IQVIA™ market value of approximately $1.3 billion for the twelve months ending January 2020. Adderall XR® is a once-daily central nervous system stimulant and is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

This generic Adderall XR® product is jointly owned by Elite and SunGen Pharma LLC ("SunGen") and is the second product launched from their collaboration. Elite will manufacture and package the generic product on a cost-plus basis. Lannett Company, Inc. will be the exclusive U.S. distributor for the product and will provide sales, marketing, and distribution.

About Lannett Company, Inc.

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.

About SunGen Pharma LLC

SunGen Pharma, LLC is a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products. SunGen specializes in the development of oral solid extended release and complex injectable products. SunGen has business partnerships with many US-based generic pharmaceutical companies to develop, manufacture, and sell several pharmaceutical products in the US.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, manufacturing, and packaging of niche generic products, which are then distributed by exclusive marketing partners. Elite specializes in oral sustained and controlled release drug products that have high barriers to entry. Elite owns generic products which have been licensed to TAGI Pharma, Glenmark Pharmaceuticals, Inc., USA., and Lannett Company, Inc. Elite currently has eleven approved generic products, two which are pending launch, another two generic products are filed with the FDA, and an NDA filed for SequestOx™. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite's ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of SequestOx™ by the FDA, and the actions the FDA require of Elite in order to obtain approval of the NDA. These forward-looking statements are not guarantees of future action or performance. These risks and other factors, including, without limitation, Elite's ability to obtain

sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews, and approvals by the Food and Drug Administration and other regulatory authorities and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com

SOURCE: Elite Pharmaceuticals, Inc.

ReleaseID: 583276

OCALA, FL / ACCESSWIRE / March 31, 2020 / AIM ImmunoTech (NYSE American:AIM) announces financial results for the fiscal year ended December 31, 2019, and provides a business update.

2019 Financial Highlights

As of December 31, 2019, AIM had cash, cash equivalents and marketable securities of $8.778 million, compared with $1.825 million as of December 31, 2018.

Research and development expenses for 2019 were $4.651 million, compared with $4.778 million for 2018. General and administrative expenses for 2019 were $7.039 million, compared with $6.201 million for 2018.

The net loss from continuing operations for 2019 was $9.533 million, or $2.62 per share, compared with $9.827 million, or $9.77 per share, for 2018.

Please refer to the full 10-K for complete details.

Update on COVID-19 Pandemic Response

Since the outbreak of SARS-CoV-2 – which causes the disease COVID-19 – AIM has been actively engaged in determining whether its drug Ampligen could be an effective treatment for this virus. The company believe that prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects against the new virus as both a protective prophylaxis and an early-onset therapy.

AIM has reached several significant COVID-19 milestones over the past two months:

AIM filed provisional patent applications to secure the company's intellectual property before seeking domestic and international research partners.
Japan's National Institute of Infectious Diseases (NIID) agreed to experiment with Ampligen as a potential treatment for COVID-19. The testing and research will be conducted by laboratories at the NIID and the University of Tokyo. AIM will report immediately upon receipt of results.
AIM engaged ChinaGoAbroad (CGA) to facilitate pre-clinical and clinical trials of Ampligen in the People's Republic of China (PRC).
AIM is in discussions with GP-Pharm in Argentina to advance Ampligen for potential use against COVID-19. Ampligen is an approved drug in Argentina for use against myalgic encephalomyelitis/chronic fatigue syndrome.
AIM is in discussions in The Netherlands – where Ampligen was recently used to treat pancreatic cancer patients – to explore expedited pre-clinical and clinical trials of Ampligen.

AIM is currently targeting the United States, Europe, Asia and Argentina for new clinical trials and, as necessary steps before clinical trials could begin, the company is in the process of soliciting one or more sites and qualified principal investigators in one or more countries. Protocols for potential clinical trial are in the final stages of development. AIM intends, as a next step, to as rapidly as possible seek Institutional Review Board approvals and governmental authorizations to commence the clinical trials of Ampligen as both a protective prophylaxis and an early-onset therapy.

Update on Cancer Clinical Trials/Programs

Six Ampligen clinical trials are currently underway at university cancer centers testing whether tumor microenvironments can be reprogrammed to increase the effectiveness of cancer immunotherapy, including checkpoint inhibitors. The company will promptly update stockholders and the market as more information on these studies becomes available. Cancer patients are especially at risk with COVID-19. AIM recognizes that all cancer centers, like all medical facilities, must make the pandemic their priority. Therefore, there is the potential for delays in clinical trial enrollment and reporting in ongoing studies in cancer patients as a consequence of the COVID-19 medical emergency.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 in humans and no assurance can be given that it will be the case. Some of the world's largest pharmaceutical companies are racing to find a treatment for COVID-19. Even if Ampligen proves effective in combating the virus, no assurance can be given that our actions toward proving this will be given first priority or that, even if Ampligen proves effective, another treatment that eventually proves effective will not make our efforts ultimately unproductive. No assurance can be given that future studies will not result in findings that are different from those reported in studies we are relying on. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks. With regard to the Company's activities with Ampligen generally, no assurance can be given as to whether current or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Any forward-looking statements set forth herein speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The information found on our website is not incorporated by reference herein and is included for reference purposes only.

Contacts:

Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com

AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com

SOURCE: AIM ImmunoTech Inc.

ReleaseID: 583177